Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RMD

Resmed Inc

Feb 06 • 04:00PM ET

271.63

+4.58 1.72 %

Healthcare • Medical Instruments & Supplies • USA • NYSE

Peers: EW BAX BDX ZBH VNT IART TFX COO HSIC XRAY

| Held by: VTI VOO VO IVV SPY VUG VOT XLV RDVY VIG

Scroll to Statements

Index	S&P 500	P/E	26.85	EPS (ttm)	10.12	Insider Own	0.64%	Shs Outstand	145.66M	Perf Week	5.16%
Market Cap	39.57B	Forward P/E	22.13	EPS next Y	12.27	Insider Trans	-6.74%	Shs Float	144.75M	Perf Month	9.44%
Enterprise Value	38.99B	PEG	1.84	EPS next Q	2.81	Inst Own	66.54%	Short Float	7.90%	Perf Quarter	10.77%
Income	1.49B	P/S	7.33	EPS this Y	15.79%	Inst Trans	0.22%	Short Ratio	10.94	Perf Half Y	-3.05%
Sales	5.40B	P/B	6.26	EPS next Y	11.00%	ROA	19.00%	Short Interest	11.43M	Perf YTD	12.77%
Book/sh	43.39	P/C	27.74	EPS next 5Y	12.04%	ROE	25.68%	52W High	293.81 -7.55%	Perf Year	11.98%
Cash/sh	9.79	P/FCF	22.09	EPS past 3/5Y	21.50% 17.37%	ROIC	21.60%	52W Low	199.92 35.87%	Perf 3Y	18.61%
Dividend Est.	2.44 (0.90%)	EV/EBITDA	18.64	Sales past 3/5Y	12.88% 11.72%	Gross Margin	60.01%	Volatility	3.11% 2.70%	Perf 5Y	34.03%
Dividend TTM	2.26 (0.83%)	EV/Sales	7.22	EPS Y/Y TTM	19.47%	Oper. Margin	34.19%	ATR (14)	6.63	Perf 10Y	379.07%
Dividend Ex-Date	Feb 12, 2026	Quick Ratio	2.32	Sales Y/Y TTM	9.57%	Profit Margin	27.53%	RSI (14)	67.44	Recom	1.90
Dividend Gr. 3/5Y	8.06% 6.33%	Current Ratio	3.06	EPS Q/Q	14.79%	SMA20	5.38%	Beta	0.86	Target Price	307.90
Payout	22.30%	Debt/Eq	0.13	Sales Q/Q	10.98%	SMA50	7.68%	Rel Volume	1.44	Prev Close	267.05
Employees	10600	LT Debt/Eq	0.09	Earnings	Jan 29 AMC	SMA200	4.81%	Avg Volume	1.05M	Price	271.63
IPO	Jun 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.34% 1.57%	Trades		Volume	1,502,494	Change	1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Downgrade	Robert W. Baird	Outperform → Neutral	$275
Sep-18-25	Initiated	Citigroup	Buy	$330
Sep-02-25	Upgrade	CLSA	Hold → Outperform
Jul-15-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$294
Mar-19-25	Initiated	Morgan Stanley	Overweight	$280
Mar-19-25	Initiated	Morgan Stanley	Overweight
Jan-16-25	Initiated	Goldman	Buy
Jan-10-25	Initiated	Piper Sandler	Neutral	$252
Dec-13-24	Initiated	Stifel	Hold	$250
Sep-24-24	Initiated	Robert W. Baird	Outperform	$280
Sep-18-24	Downgrade	Wolfe Research	Peer Perform → Underperform	$180
Sep-04-24	Downgrade	Needham	Buy → Hold
Jun-25-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-24-24	Downgrade	Citigroup	Buy → Neutral
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight	$227
Oct-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$180 → $169
Oct-12-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$273 → $202
Oct-09-23	Upgrade	JP Morgan	Neutral → Overweight	$210 → $170
Sep-29-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-06-23	Upgrade	Needham	Hold → Buy	$180

Show Previous Ratings

Feb-06-26 08:22PM	Analyst Report: ResMed Inc. (Morningstar Research)
08:03AM	RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand (Zacks)
Feb-05-26 08:09AM	ALGN Stock Climbs on Q4 Earnings and Revenue Beat, Margins Down (Zacks)
12:44AM	The Top 5 Analyst Questions From ResMed's Q4 Earnings Call (StockStory)
Feb-03-26 12:02PM	Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions (Zacks)
11:18AM	Loading…
11:18AM	Silver Economy Boom: Investing in Healthcare's Aging Tailwinds (Zacks)
05:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Revised) (Zacks)
Feb-02-26 08:53PM	ResMed Inc. (RMD): A Bull Case Theory (Insider Monkey)
09:42AM	IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
09:08AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Jan-30-26 01:08PM	Analysts Maintain Bull Case On ResMed Despite Competition Concerns (Benzinga)
11:45AM	Analyst Report: ResMed Inc. (Morningstar Research)
01:36AM	ResMed Q2 Earnings Call Highlights (MarketBeat)
12:33AM	RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth (StockStory)
12:04AM	ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations (GuruFocus.com)
05:30PM	Loading…
Jan-29-26 05:30PM	ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	ResMed (RMD) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:07PM	ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations (StockStory)
04:15PM	ResMed: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 (GlobeNewswire)
09:50AM	Here's Why ResMed (RMD) is a Strong Momentum Stock (Zacks)
09:40AM	Are Medical Stocks Lagging ResMed (RMD) This Year? (Zacks)
08:32AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Jan-28-26 12:10PM	Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:24AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
Jan-27-26 10:08PM	ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
11:52AM	UnitedHealth Q4 Earnings Beat on Strong Optum Rx, Offers 2026 Outlook (Zacks)
09:15AM	Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics (Zacks)
07:54AM	Resmed's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-26-26 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
10:00AM	Loading…
Jan-22-26 10:00AM	ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
06:13AM	AdvaMed leaders on tariffs, MDUFA and wearables (MedTech Dive)
Jan-15-26 09:22AM	Bet on These 5 Low-Leverage Stocks to Avoid Industrial Volatilities (Zacks)
08:30AM	Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today (Zacks)
Jan-14-26 10:37PM	Reflecting On Patient Monitoring Stocks' Q3 Earnings: ResMed (NYSE:RMD) (StockStory)
Jan-13-26 11:04PM	ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
09:50AM	Why ResMed (RMD) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-08-26 04:05PM	Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 (GlobeNewswire)
09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
07:57AM	Is This the Right Time to Add Resmed Stock to Your Portfolio? (Zacks)
Jan-05-26 03:57AM	What You Need to Know Ahead of ResMed's Earnings Release (Barchart)
Dec-30-25 12:45PM	Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
08:20AM	Buy These 5 Low-Leverage Stocks Amid a Reversal of Santa Claus Rally (Zacks)
08:20AM	BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now? (Zacks)
07:33AM	3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium (Zacks)
Dec-23-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
Dec-18-25 04:05PM	Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 11:35PM	2 Healthcare Stocks on Our Watchlist and 1 We Brush Off (StockStory)
Dec-12-25 04:32AM	Mick Farrell named chair of AdvaMed board (MedTech Dive)
Dec-09-25 07:26AM	RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort (Zacks)
Dec-08-25 09:00AM	Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy (GlobeNewswire)
08:58AM	Is ResMed Stock Underperforming the S&P 500? (Barchart)
Dec-05-25 11:30AM	Why Is Phibro (PAHC) Down 5.3% Since Last Earnings Report? (Zacks)
Dec-03-25 08:14AM	Should You Continue to Hold RMD Stock in Your Portfolio? (Zacks)
Dec-01-25 06:03AM	1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds (StockStory)
Nov-20-25 07:10AM	Are Wall Street Analysts Predicting ResMed Stock Will Climb or Sink? (Barchart)
Nov-17-25 05:11AM	Resmed CEO Mick Farrell on new technologies, tariffs and AI (MedTech Dive)
Nov-12-25 02:00PM	Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete? (Motley Fool)
Nov-11-25 04:37PM	Top Stock Reports for Exxon Mobil, Home Depot & NextEra Energy (Zacks)
Nov-06-25 12:35AM	ResMed's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Oct-31-25 08:47AM	RMD Q3 Deep Dive: ResMed Launches New Mask Platform and Invests in U.S. Operations (StockStory)
08:22AM	Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand (Zacks)
12:17AM	Analyst Report: ResMed Inc. (Morningstar Research)
Oct-30-25 11:01PM	ResMed Inc (RMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations (GuruFocus.com)
08:18PM	Analyst Report: ResMed Inc. (Morningstar Research)
05:30PM	Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	ResMed (RMD) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:17PM	ResMed: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	ResMed (NYSE:RMD) Reports Q3 In Line With Expectations (StockStory)
04:05PM	Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 (GlobeNewswire)
Oct-29-25 09:15AM	Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Oct-28-25 11:03PM	ResMed (RMD) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-27-25 10:33AM	Do Options Traders Know Something About ResMed Stock We Don't? (Zacks)
Oct-24-25 12:45AM	1 Healthcare Stock to Research Further and 2 We Ignore (StockStory)
Oct-23-25 10:00AM	ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-22-25 05:57PM	ResMed Inc. (RMD): A Bull Case Theory (Insider Monkey)
01:25PM	GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring (Zacks)
Oct-21-25 10:06AM	HIMS Stock Declines Despite Launch of New Specialty in Women's Health (Zacks)
Oct-20-25 11:46AM	Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren (Zacks)
09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
Oct-17-25 06:42PM	Top Analyst Reports for Home Depot, Boeing & Progressive (Zacks)
10:49AM	4 GARP Stocks That Investors Can Scoop Up for Maximum Returns (Zacks)
Oct-15-25 01:56PM	GEHC Stock Up Following New Launch to Streamline Perinatal Workflow (Zacks)
08:40AM	Abbott (ABT) Q3 Earnings Meet Estimates (Zacks)
Oct-13-25 01:14PM	BD Stock Down Despite Making Progress in the Treatment of PAD Lesions (Zacks)
05:47AM	Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo (Zacks)
Oct-10-25 01:12PM	BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow (Zacks)
10:32AM	5 Low-Leverage Stocks to Buy as Market Takes a Tumble (Zacks)
Oct-09-25 04:05PM	Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 (GlobeNewswire)
08:15AM	Neogen (NEOG) Q1 Earnings Lag Estimates (Zacks)
Oct-08-25 12:44PM	PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell (Zacks)
Oct-07-25 08:04AM	What to Expect From ResMed's Next Quarterly Earnings Report (Barchart)
Oct-02-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
09:10AM	Nyxoah Expands in the Middle East to Provide Wider Access to Genio (Zacks)
Sep-25-25 10:07AM	Zacks.com featured highlights include GE Aerospace, ResMed, Vertiv and National Fuel Gas (Zacks)
Sep-24-25 09:32AM	Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns (Zacks)
Sep-18-25 08:52AM	Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring (Zacks)
Sep-16-25 04:05PM	Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 (GlobeNewswire)
Sep-15-25 02:07AM	How Is ResMed's Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Sep-12-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FARRELL PETER C	Director	Feb 04 '26	Sale	251.31	2,000	502,620	64,773	Feb 06 11:07 AM
Rider Michael J	Global General Counsel	Feb 04 '26	Sale	260.00	50	13,000	9,691	Feb 06 11:05 AM
Peter C Farrell	Director	Feb 04 '26	Proposed Sale	251.27	2,000	502,540		Feb 04 06:53 PM
Rider Michael J	Officer	Feb 04 '26	Proposed Sale	260.00	50	13,000		Feb 04 10:59 AM
Sandercock Brett	Chief Financial Officer	Feb 02 '26	Sale	257.03	1,000	257,030	85,495	Feb 03 03:06 PM
Sandercock Brett	Officer	Feb 02 '26	Proposed Sale	257.03	1,000	257,030		Feb 02 03:15 PM
FARRELL PETER C	Director	Jan 07 '26	Sale	248.83	2,000	497,660	66,773	Jan 09 07:33 AM
Farrell Michael J.	Chairman and CEO	Jan 07 '26	Option Exercise	146.34	4,991	730,383	471,214	Jan 08 03:23 PM
Farrell Michael J.	Chairman and CEO	Jan 07 '26	Sale	248.46	4,991	1,240,065	466,223	Jan 08 03:23 PM
Peter C Farrell	Director	Jan 07 '26	Proposed Sale	248.79	2,000	497,580		Jan 07 05:03 PM
Farrell Michael J.	Officer	Jan 07 '26	Proposed Sale	248.46	4,991	1,240,065		Jan 07 04:17 PM
Sandercock Brett	Chief Financial Officer	Jan 02 '26	Sale	241.75	1,000	241,750	86,495	Jan 05 05:27 PM
Rider Michael J	Global General Counsel	Jan 02 '26	Sale	241.75	50	12,088	9,741	Jan 05 01:18 PM
Sandercock Brett	Officer	Jan 02 '26	Proposed Sale	241.75	1,000	241,750		Jan 02 12:45 PM
Rider Michael J	Officer	Jan 02 '26	Proposed Sale	241.75	50	12,088		Jan 02 10:56 AM
Farrell Michael J.	Chairman and CEO	Dec 08 '25	Option Exercise	146.34	4,991	730,383	471,214	Dec 09 03:17 PM
Farrell Michael J.	Chairman and CEO	Dec 08 '25	Sale	251.41	4,991	1,254,796	466,223	Dec 09 03:17 PM
Farrell Michael J.	Officer	Dec 08 '25	Proposed Sale	251.41	4,991	1,254,796		Dec 08 04:13 PM
FARRELL PETER C	Director	Dec 03 '25	Sale	251.47	2,000	502,940	68,773	Dec 04 01:46 PM
Peter C Farrell	Director	Dec 03 '25	Proposed Sale	251.43	2,000	502,860		Dec 03 04:20 PM
Rider Michael J	Global General Counsel	Dec 01 '25	Sale	244.16	50	12,208	9,791	Dec 02 04:27 PM
Sandercock Brett	Chief Financial Officer	Dec 01 '25	Sale	244.16	1,000	244,160	87,495	Dec 02 04:23 PM
Sandercock Brett	Officer	Dec 01 '25	Proposed Sale	244.16	1,000	244,160		Dec 01 12:11 PM
Rider Michael J	Officer	Dec 01 '25	Proposed Sale	244.16	50	12,208		Dec 01 12:08 PM
De Witte Jan	Director	Nov 25 '25	Sale	255.00	2,055	524,025	4,261	Nov 26 02:40 PM
De Witte Jan	Director	Nov 25 '25	Proposed Sale	255.00	2,055	524,025		Nov 25 03:22 PM
FARRELL PETER C	Director	Nov 14 '25	Option Exercise	101.64	11,442	1,162,965	77,552	Nov 18 04:59 PM
FARRELL PETER C	Director	Nov 12 '25	Sale	252.05	2,000	504,100	66,110	Nov 13 05:39 PM
De Witte Jan	Director	Nov 11 '25	Sale	250.25	487	121,872	5,319	Nov 13 05:24 PM
Peter C Farrell	Director	Nov 12 '25	Proposed Sale	252.05	2,000	504,100		Nov 12 05:21 PM
De Witte Jan	Director	Nov 11 '25	Proposed Sale	250.25	487	121,872		Nov 12 06:44 AM
Farrell Michael J.	Chairman and CEO	Nov 07 '25	Option Exercise	101.64	8,011	814,238	475,877	Nov 10 07:07 PM
Farrell Michael J.	Chairman and CEO	Nov 07 '25	Sale	249.75	8,011	2,000,773	467,866	Nov 10 07:07 PM
Farrell Michael J.	Officer	Nov 07 '25	Proposed Sale	249.75	8,011	2,000,773		Nov 07 04:12 PM
Sandercock Brett	Chief Financial Officer	Nov 03 '25	Option Exercise	101.64	2,000	203,280	88,745	Nov 04 04:02 PM
Sandercock Brett	Chief Financial Officer	Nov 03 '25	Sale	247.54	3,000	742,620	85,745	Nov 04 04:02 PM
Sandercock Brett	Officer	Nov 03 '25	Proposed Sale	247.54	3,000	742,620		Nov 03 10:25 AM
Farrell Michael J.	Chief Executive Officer	Oct 07 '25	Option Exercise	101.64	8,009	814,035	475,801	Oct 09 11:03 AM
Farrell Michael J.	Chief Executive Officer	Oct 07 '25	Sale	282.85	8,009	2,265,332	467,792	Oct 09 11:03 AM
Farrell Michael J.	Officer	Oct 07 '25	Proposed Sale	282.85	8,009	2,265,332		Oct 07 04:10 PM
Ghoshal Kaushik	Former Officer	Oct 07 '25	Proposed Sale	283.42	4,876	1,381,956		Oct 07 01:49 PM
Sandercock Brett	Chief Financial Officer	Oct 01 '25	Option Exercise	101.64	2,000	203,280	89,745	Oct 03 12:56 PM
Sandercock Brett	Chief Financial Officer	Oct 01 '25	Sale	274.36	3,000	823,080	86,745	Oct 03 12:56 PM
Rider Michael J	Global General Counsel	Oct 01 '25	Sale	274.36	100	27,436	11,327	Oct 02 04:32 PM
Rider Michael J	Officer	Oct 01 '25	Proposed Sale	274.36	100	27,436		Oct 01 11:42 AM
Sandercock Brett	Officer	Oct 01 '25	Proposed Sale	274.36	3,000	823,080		Oct 01 10:34 AM
Farrell Michael J.	Chief Executive Officer	Sep 08 '25	Option Exercise	101.64	8,009	814,035	475,801	Sep 09 04:10 PM
Farrell Michael J.	Chief Executive Officer	Sep 08 '25	Sale	278.14	8,009	2,227,590	467,792	Sep 09 04:10 PM
Farrell Michael J.	Officer	Sep 08 '25	Proposed Sale	278.14	8,009	2,227,591		Sep 08 04:22 PM
Sandercock Brett	Chief Financial Officer	Sep 02 '25	Option Exercise	101.64	2,000	203,280	90,745	Sep 03 05:39 PM
Sandercock Brett	Chief Financial Officer	Sep 02 '25	Sale	270.77	3,000	812,310	87,745	Sep 03 05:39 PM
Sandercock Brett	Officer	Sep 02 '25	Proposed Sale	270.77	3,000	812,310		Sep 02 12:02 PM
Hernandez John	Director	Aug 18 '25	Option Exercise	148.90	2,575	383,418	6,620	Aug 19 01:10 PM
Hernandez John	Director	Aug 18 '25	Sale	287.10	2,575	739,289	4,045	Aug 19 01:10 PM
Hernandez John	Director	Aug 18 '25	Proposed Sale	287.10	2,575	739,289		Aug 18 03:11 PM
Farrell Michael J.	Chief Executive Officer	Aug 07 '25	Option Exercise	101.64	8,009	814,035	463,512	Aug 11 10:45 AM
Farrell Michael J.	Chief Executive Officer	Aug 07 '25	Sale	279.48	8,009	2,238,379	455,503	Aug 11 10:45 AM
Farrell Michael J.	Officer	Aug 07 '25	Proposed Sale	282.83	8,009	2,265,185		Aug 07 11:20 AM
Sandercock Brett	Chief Financial Officer	Aug 01 '25	Option Exercise	101.64	2,000	203,280	86,283	Aug 05 12:16 PM
Sandercock Brett	Chief Financial Officer	Aug 01 '25	Sale	281.90	3,000	845,700	83,283	Aug 05 12:16 PM
Rider Michael J	Global General Counsel	Aug 01 '25	Sale	281.90	50	14,095	8,486	Aug 04 07:55 PM
Rider Michael J	Officer	Aug 01 '25	Proposed Sale	281.90	50	14,095		Aug 01 11:52 AM
Sandercock Brett	Officer	Aug 01 '25	Proposed Sale	281.90	3,000	845,700		Aug 01 11:07 AM
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Option Exercise	101.64	8,009	814,035	463,512	Jul 09 08:37 AM
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Sale	256.72	8,009	2,056,076	455,503	Jul 09 08:37 AM
Farrell Michael J.	Officer	Jul 07 '25	Proposed Sale	256.72	8,009	2,056,076		Jul 07 05:21 PM
FARRELL PETER C	Director	Jul 02 '25	Sale	255.49	945	241,438	68,273	Jul 03 12:01 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Option Exercise	101.64	2,883	293,028	88,166	Jul 02 05:53 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Sale	256.99	3,883	997,892	84,283	Jul 02 05:53 PM
FARRELL PETER C	Director	Jul 02 '25	Proposed Sale	264.55	945	250,000		Jul 02 04:15 PM
Rider Michael J	Global General Counsel	Jul 01 '25	Sale	256.99	66	16,961	8,536	Jul 02 03:57 PM
Rider Michael J	Officer	Jul 01 '25	Proposed Sale	256.99	66	16,961		Jul 01 12:40 PM
Sandercock Brett	Officer	Jul 01 '25	Proposed Sale	256.99	3,883	997,892		Jul 01 10:35 AM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Option Exercise	101.64	8,009	814,035	463,512	Jun 10 06:35 PM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Sale	251.21	8,009	2,011,910	455,503	Jun 10 06:35 PM
Farrell Michael J.	Officer	Jun 09 '25	Proposed Sale	252.00	8,009	2,018,268		Jun 09 10:26 AM
FARRELL PETER C	Director	Jun 04 '25	Sale	247.32	2,000	494,640	69,218	Jun 06 03:22 PM
FARRELL PETER C	Director	Jun 04 '25	Proposed Sale	250.00	2,000	500,000		Jun 04 07:19 PM
Sandercock Brett	Chief Financial Officer	Jun 02 '25	Sale	243.78	1,000	243,780	85,283	Jun 03 05:59 PM
Rider Michael J	Global General Counsel	Jun 02 '25	Sale	243.78	41	9,995	8,870	Jun 03 01:13 PM
Rider Michael J	Officer	Jun 02 '25	Proposed Sale	243.78	41	9,995		Jun 02 01:42 PM
Sandercock Brett	Officer	Jun 02 '25	Proposed Sale	243.78	1,000	243,780		Jun 02 09:58 AM
Sandercock Brett	Chief Financial Officer	May 22 '25	Sale	244.59	3,644	891,286	86,283	May 27 10:24 AM
Sandercock Brett	Officer	May 22 '25	Proposed Sale	244.59	3,644	891,286		May 22 10:25 AM
De Witte Jan	Director	May 20 '25	Sale	243.47	2,000	486,940	5,806	May 22 10:05 AM
De Witte Jan	Director	May 20 '25	Proposed Sale	243.47	2,000	486,940		May 20 11:25 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Option Exercise	101.64	8,009	814,035	463,512	May 09 11:01 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Sale	243.23	8,009	1,948,003	455,503	May 09 11:01 AM
FARRELL PETER C	Director	May 07 '25	Sale	242.25	2,000	484,500	71,218	May 08 05:38 PM
FARRELL PETER C	Director	May 07 '25	Proposed Sale	250.00	2,000	500,000		May 07 08:12 PM
Farrell Michael J.	Officer	May 07 '25	Proposed Sale	243.23	8,009	1,948,003		May 07 04:14 PM
Sandercock Brett	Chief Financial Officer	Apr 08 '25	Sale	215.58	1,000	215,580	89,864	Apr 10 06:14 PM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Option Exercise	101.64	8,009	814,035	463,482	Apr 09 10:52 AM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Sale	209.85	8,009	1,680,699	455,472	Apr 09 10:52 AM
Sandercock Brett	Officer	Apr 08 '25	Proposed Sale	215.58	1,000	215,580		Apr 08 09:43 AM
Farrell Michael J.	Officer	Apr 07 '25	Proposed Sale	209.85	8,009	1,680,699		Apr 07 04:15 PM
FARRELL PETER C	Director	Apr 02 '25	Sale	219.74	2,000	439,480	73,218	Apr 04 12:47 PM
Rider Michael J	Global General Counsel	Apr 01 '25	Sale	222.86	64	14,263	8,846	Apr 03 12:59 PM
FARRELL PETER C	Director	Apr 02 '25	Proposed Sale	222.30	2,000	444,600		Apr 02 05:00 PM
Rider Michael J	Officer	Apr 01 '25	Proposed Sale	222.86	64	14,263		Apr 01 11:08 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RMD

Resmed Inc

Upgrade your FINVIZ experience